Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14 & mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treated patients With aHCC
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & ...
Author: Annual-Meeting
Added: 06/13/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts